Deutsche Bank
VRDN icon

Deutsche Bank’s Viridian Therapeutics VRDN Stock Holding History

Deutsche Bank’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.87M Sell
482,875
-549,441
-53% -$8.85M ﹤0.01% 1113
2026
Q1 		$20.2M Buy
1,032,316
+552,558
+115% +$16.4M 0.01% 847
2025
Q4 		$14.9M Sell
479,758
-457,709
-49% -$12.6M ﹤0.01% 965
2025
Q3 		$20.2M Buy
937,467
+550,529
+142% +$9.93M 0.01% 855
2025
Q2 		$5.41M Sell
386,938
-9,870
-2% -$134K ﹤0.01% 1209
2025
Q1 		$5.35M Sell
396,808
-6,066
-2% -$103K ﹤0.01% 1227
2024
Q4 		$7.72M Buy
402,874
+23,327
+6% +$507K ﹤0.01% 1126
2024
Q3 		$8.63M Buy
379,547
+331,102
+683% +$5.41M ﹤0.01% 1061
2024
Q2 		$630K Buy
48,445
+1,672
+4% +$23.1K ﹤0.01% 2223
2024
Q1 		$819K Buy
46,773
+3,982
+9% +$77.2K ﹤0.01% 2105
2023
Q4 		$932K Buy
42,791
+20,768
+94% +$328K ﹤0.01% 2067
2023
Q3 		$338K Sell
22,023
-70,631
-76% -$1.35M ﹤0.01% 2431
2023
Q2 		$2.2M Sell
92,654
-161,460
-64% -$4.14M ﹤0.01% 1575
2023
Q1 		$6.46M Buy
254,114
+237,028
+1,387% +$7.6M ﹤0.01% 1125
2022
Q4 		$499K Buy
17,086
+6,005
+54% +$138K ﹤0.01% 2450
2022
Q3 		$227K Sell
11,081
-1,687
-13% -$30.3K ﹤0.01% 2873
2022
Q2 		$148K Buy
+12,768
New +$172K ﹤0.01% 3330
2020
Q1 		– Sell
-1,424
Closed -$10K – 4855
2019
Q4 		$10K Sell
1,424
-1,212
-46% -$12.4K ﹤0.01% 4499
2019
Q3 		$28K Sell
2,636
-7,569
-74% -$167K ﹤0.01% 4206
2019
Q2 		$313K Sell
10,205
-1,624
-14% -$65.2K ﹤0.01% 3567
2019
Q1 		$494K Sell
11,829
-881
-7% -$39.9K ﹤0.01% 3458
2018
Q4 		$577K Buy
12,710
+8,786
+224% +$508K ﹤0.01% 3236
2018
Q3 		$328K Buy
3,924
+654
+20% +$61.7K ﹤0.01% 3998
2018
Q2 		$315K Sell
3,270
-350
-10% -$37K ﹤0.01% 4076
2018
Q1 		$380K Sell
3,620
-441
-11% -$47.9K ﹤0.01% 3867
2017
Q4 		$634K Buy
4,061
+3,305
+437% +$421K ﹤0.01% 3483
2017
Q3 		$102K Sell
756
-209
-22% -$35.2K ﹤0.01% 4161
2017
Q2 		$185K Buy
+965
New +$163K ﹤0.01% 3968
2017
Q1 		– Sell
-71
Closed -$5K – 5112
2016
Q4 		$5K Buy
+71
New +$7.42K ﹤0.01% 4757

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Deutsche Bank's VRDN Position: Q2 2026 in Review

Deutsche Bank reduced its Viridian Therapeutics (VRDN) stake by 53% in Q2 2026, selling an estimated $8.85M and leaving 482,875 shares worth $8.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1113.

Deutsche Bank first reported a position in VRDN in Q4 2016 and has held it in 29 quarters since. The position peaked at $20.2M in Q3 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Deutsche Bank held 482,875 shares of Viridian Therapeutics worth $8.87M as of Q2 2026.
  • Deutsche Bank sold 549,441 Viridian Therapeutics shares in Q2 2026, an estimated $8.85M.
  • Viridian Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1113 holding.
  • Deutsche Bank first reported a position in Viridian Therapeutics in Q4 2016 and has held it in 29 quarters since.
  • Deutsche Bank's Viridian Therapeutics position peaked at $20.2M in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.